Abstract
The objective of this study was to explore the therapeutic effect and influence on the immune function of combining percutaneous targeted argon-helium cryoablation with chemotherapy in treating non-small cell lung cancer (NSCLC). Totally 40 patients with NSCLC were randomly devided into 20 cases of receiving control group (targeted chemotherapy) and 20 cases of experimental group (targeted cryoablation plus chemotherapy). In patients with a combination of treatment, the response rate of experimental group was 80% (16/20) and CR was 20% (4/20), but the response rate of control group was 45% (9/20) and CR was 0; In the experimental group, T cell subsets CD3 +, CD4 +, CD4 +/CD8 + ratio were significantly elevated, as compared with the baselines (P<0.05), which were not significantly elevated in the control group. In conclusion, combining percutaneous targeted argon-helium cryoablation with chemotherapy is an effective way to treat intermediate and advanced NSCLC patients, Ar-He targeted cryoablation regulates and stimulates self immunological function of NSCLC patients.
| Original language | English (US) |
|---|---|
| Journal | Chinese Journal of Cancer Prevention and Treatment |
| Volume | 18 |
| Issue number | 14 |
| State | Published - Jul 28 2011 |
Keywords
- Argon/therapeutic uses
- Carcinoma
- Cryotherapy
- Helium/therapeutic uses
- Lung neoplasms/therapy
- Non-small cell lung/therapy
ASJC Scopus subject areas
- Oncology
Fingerprint
Dive into the research topics of 'Clinical observation on therapeutic effect of combining percutaneous targeted argon-helium cryoablation in treating NSCLC by chemotherapy'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS